🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I'm running the Rock the Ridge 50-mile relay w/ my Swarthmore Athletics teammates to celebrate our 40th bdays and as a fundraiser for Mohonk Preserve.  If interested, pls consider supporting our team. More info charity.pledgeit.org/f/PPPUMB5bby (Note: there are many worthy causes for your⏲️& 💵)

Congratulations Phil Kantoff -- Hard to imagine anyone more deserving.

A terrific step in bringing our anti-PSMA alpha-emitting radioantibody to patients. #PSMA #prostatecaner

Very happy to have Andres Ricaurte Fajardo represent the WCM Molecular Imaging and Therapeutics group!

Congratulations to the whole group and especially first author Yajas Shah !

A totally unbiased and objective congratulations to the ORIGINAL Dr. Nauseef.

Thanks to all who supported. I cannot recommend more strongly running a 50 mile relay with three of your pals. Truly wonderful. I might also recommend actually training for it . . . but we all made it through uninjured and with 3rd place in the male relay division. Limping today.

Congratulations to Himanshu Nagar ! A rare combination of forward-thinking academically innovative in his field and patient-focused — plus a terrific person. (More) big things to come in GURO as led by Himanshu!

A few pre-ASCO miles along the lake - and a bonus Jessica Hawley MD MS sighting! #ASCO24

.Scott Tagawa shared #ClinicalTrial results at #ASCO24 evaluating fractionated doses of the radioligand therapy 177Lu-PSMA-617 for metastatic castration-resistant #ProstateCancer: bit.ly/3VmbbG2

Hot flashes significantly impact pts on ADT. As led by Bradley Stish in a double blinded, placebo controlled Alliance for Clinical Trials in Oncology study, oxybutynin significantly improves hot flashes a/w ADT (⬇️ #, frequency, & burden). The tx was well tolerated. Good news for pts w/ prostate cancer! #ASCO24

In Chicago Scott Tagawa and Andres Ricaurte Fajardo presented our collaborative phase I/II dose-escalation clinical trial results at #ASCO24 evaluating fractionated doses of the radioligand therapy 177Lu-PSMA-617 for mCRPC @JOsbMD Sandra Huicochea Castellanos : bit.ly/3VmbbG2

Dr. Jones Nauseef, MD PhD, Senior Medical Director at Convergent Therapeutics will present an update on our Actinium-225 PSMA-targeted radioantibody, CONV01-α at the 2024 Targeted Radiopharmaceuticals Summit. For more, visit:bit.ly/3yd5m56 #ProstateCancer #oncology #PSMA

Looking forward to discussing all the promise of our anti-#PSMA radioantibody and learning from colleagues in the targeted radiotherapy space. See you in San Diego!

.Kevin Liou from Memorial Sloan Kettering Cancer Center reviewing evidence-based integrative medicine for men with #ProstateCancer. #NYCProstateSummit

Kevin always with great insight.

Very happy to speak on this topic and see my friend and former residency brother Tariq Chukir

Congratulations! Among many highlights of my time at Cornell was having as an office neighbor Dr. Bishoy M. Faltas: a big thinker who knows how to go from an observation 👉🏼 a clever idea 👉🏼 practical execution 👉🏼 insightful conclusions. Grateful to have played a small role in this one.

Best part of my day was when my wife said “now you’re thinking like Columbo!” when we were discussing a recent The New York Times The Ethicist query.